News Archive // Chi-Med

HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects

CLSA Investors' Forum

2016 Half-Year Financial Results

ASCO 2016: Safety profile and preliminary clinical efficacy of epitinib in EGFRm+ NSCLC

ASCO 2016: Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer

AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression

2015 Full Year Results Presentation

EORTC 2015: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

ESMO 2015: Phase II trial of fruquintinib in metastatic colorectal cancer

2015 Interim Results Presentation

2015 Deutsche Bank Healthcare Conference (Boston)

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Overview of Chi-Med

2014 Full Year Results Presentation

2015 JP Morgan Healthcare Conference (San Francisco)

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)

ACR/ARHP 2014: HM-0523 (HMPL-523), a novel Syk inhibitor, blocks glomerulonephritis and extends life spans in lupus prone MRL/lpr mice

2014 R&D Briefing

Discovery of [savolitinib] as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (Journal of Medicinal Chemistry 2014)

2014 Interim Results Presentation

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors

AACR 2014: Discovery and Early Development of HMPL-504 (savolitinib)

AACR 2014: Targeting MET in preclinical models to support the clinical development of AZD6094/HMPL-504 (savolitinib) in NSCLC

AACR 2014: Anti-tumour activity of Epitinib in patient derived esophagus cancer models

2013 Full Year Results Presentation

ACR 2013: HMPL-523, a novel Syk inhibitor, significantly ameliorates the severity of arthritis in rodents

2013 R&D Briefing

2013 Interim Results Presentation

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors

AACR 2013: Preclinical disposition and pharmacokinetics of savolitinib, a novel selective cMet inhibitor

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer

2012 Full Year Results Presentation

HMPL-004 (Andrographis paniculata extract) Prevents Development of Murine Colitis by Inhibiting T-cell Proliferation and TH1/TH17 Responses (Inflammatory Bowel Diseases 2013)

Chi-Med/Nestlé Health Science Analyst Conference Call Transcript

ISSX 2012: Pharmacokinetic/Pharmacodynamic Modeling of Epitinib to Evaluate the Anti-cancer Effect on A431 Tumor Xenograft in Nude Mice

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis (American Journal of Gastroenterology 2013)

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors

AACR 2011: Savolitinib (HMPL-504) against subcutaneous xenograft and orthotopic brain tumor models

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine (Alimentary Pharmacology and Therapeutics 2011)

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor